Government investment in cell and gene therapy sector bears fruit

A decade on from the founding of The Cell and
Gene Therapy Catapult (CGT Catapult), the UK-based industry
accelerator is celebrating its successes.

With the publication of its
annual review
, the group aims to
highlight the continued development of the UK cell and gene
therapy sector, with 31% growth in funds raised by British
advanced therapy developers of £1.7 billion ($2.03
billion).

There has also been a 25% increase in
manufacturing space in…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

 

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

Source

Similar Posts